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Fontan surgery is the standard of care for many patients with univentricular congenital 
cardiopathies. Recent advances have improved the survival of Fontan patients, and 
nowadays most of them reach adulthood. In this setting, Fontan-associated liver disease 
has been increasingly recognized, and has become a significant prognostic factor. Liver 
nodules are considered a component of FALD yet their prevalence, imaging features 
and predictors have hardly been evaluated in large patient series. In this multicentric 
study, we prospectively assessed liver nodules in a large number of Fontan patients. 
This allowed us to conclude that liver nodules are frequent, typically hyperechoic, 
hypervascular and predominantly peripheral. The risk of hepatocellular carcinoma is 
present, and biopsy is required for its diagnosis. 
Highlights 
- Liver nodules are frequent in Fontan patients. 
- Some liver nodules may go unnoticed on abdominal ultrasound. 
- The risk of hepatocellular carcinoma is low but present. 
- Arterial hyperenhacement and washout are not specific of hepatocellular 
carcinoma in this population. Benign nodules may present arterial 
hyperenhacement and washout. 
- Hepatocellular carcinoma in Fontan patients presents with suspicious 
radiological features and elevated alpha-fetoprotein. 
 
  
RE: Ms JHEPAT-D-19-01279  
 
5
ABSTRACT (261 words) 
Background and aims: Fontan surgery is used to treat a variety of congenital heart 
malformations, and may lead to advanced chronic liver disease in the long-term. This 
study examines the prevalence, characteristics and predictors of liver nodules in patients 
with Fontan surgery.  
Methods: This was a prospective, cross-sectional and observational study conducted at 
eight European centres. Consecutive patients with Fontan surgery underwent blood 
tests, abdominal ultrasonography (US), transient elastography (Fibroscan®), 
echocardiography, hemodynamics, and abdominal MRI/CT scan. The primary outcome 
measure was liver nodules detected in the MRI/CT scan. Predictors of liver nodules 
were identified by multivariate logistic regression. 
Results: One hundred and fifty-two patients were enrolled (mean age 27.3 years). The 
mean time elapsed from surgery to inclusion was 18.3 years. Liver nodule prevalences 
were 29.6% (95% CI: 23–37%) on US and 47.7% (95% CI: 39-56%) on MRI/CT. 
Nodules were usually hyperechoic (76.5%), round-shaped (>80%), hyperenhancing in 
the arterial phase (92%) and located in the liver periphery (75%). The sensitivity and 
specificity of US were 50% (95% CI: 38-62%) and 85.3% (95% CI: 75-92%), 
respectively. Inter-imaging test agreement was low (adjusted kappa: 0.34). In the 
multivariate analysis, time since surgery > 10 years was the single independent 
predictor of liver nodules (OR: 4.18, P=0.040). Hepatocellular carcinoma was 
histologically diagnosed in 2 of the 8 patients with hypervascular and washout liver 
nodules. 
Conclusion: While liver nodules are frequent in Fontan patients, they may go unnoticed 
in US. Liver nodules are usually hyperechoic, hypervascular and predominantly 
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peripheral. This population is at risk of hepatocellular carcinoma, the diagnosis of 
which requires biopsy confirmation. 
Keywords: Fontan, heart, liver cirrhosis, liver nodules, hepatocellular carcinoma 
  




Fontan surgery (FS) is the standard of care for many patients with congenital 
cardiopathies characterised by a functionally univetricular heart. The common feature 
of these cardiac defects is the mixing of desaturated blood from the caval veins and 
oxygenated blood from the pulmonary veins in a single ventricular pump. Fontan 
circulation is a palliative strategy that aims to restore a double circulation system to 
avoid cyanosis. Improvements in surgical techniques and medical management have 
had a significant impact on survival, and nowadays most Fontan patients survive into 
adulthood [1,2]. However, systemic venous congestion and reduced systemic cardiac 
output are the hallmarks of FS, leading to long-term multiorgan complications [3,4]. 
Further, this single haemodynamic system in Fontan p tients puts the liver at risk of 
vascular damage and advanced chronic liver disease.  
Studies have shown that Fontan-associated liver disease (FALD) is an 
independent prognostic factor with a significant impact on survival [5]. Several 
retrospective single-centre studies with a limited sample size have also suggested that 
regenerative and hypervascular nodules on arterial ph se imaging are frequent in this 
population [5–8]. As for other vascular liver diseas such as Budd-Chiari syndrome 
(BCS), the diagnosis of liver nodules (LN) in FALD is a significant challenge, since 
features and risk factors for their presence are poorly documented. Besides, the findings 
of several recent small case series have raised concerns about the risk of hepatocellular 
carcinoma in Fontan patients [9–11]. The American College of Cardiology statement on 
FALD underlines the need for periodic radiologic liver assessment, although evidence-
supported recommendations are lacking [12]. 
To our knowledge, the present study is the first pros ective multicentre 
investigation designed to assess the prevalence, chara teristics, and predictor factors of 
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LN on cross-sectional imaging. As secondary objectiv s, we also addressed the 
diagnostic accuracy of abdominal ultrasonography (US) and inter-test agreement 
between US and MRI/CT in the Fontan population.  
 
MATERIAL AND METHODS 
Study design  
This was an observational, prospective, cross-sectional study conducted at eight 
European tertiary centres belonging to the VALDIG group (ww.valdig.eu). All 
consecutive patients with FS were invited to participate in the study. No exclusion 
criteria were applied. The study period was December 2015 to October 2018. The study 
protocol adhered to the principles of the Declaration of Helsinki and was approved by 
the Ethics Committees for Clinical Research of all the participating institutions (IRB 
code: 384/14, HRC-FONLIVER). Written Informed conset for inclusion in the study 
was obtained in all cases. 
Procedures and variables 
A common standardized protocol was elaborated for the assessment of FALD 
before the study outset. Patients were subjected to a structured medical interview, 
physical examination, blood tests to rule out other liver disease etiologies, abdominal 
US, liver elastography (Fibroscan®, Probe M/XL Echosens®, Paris France), abdominal 
magnetic resonance imaging (MRI) or computed tomography (CT) when MRI was 
contraindicated, and echocardiography. Biopsy was considered by the multidisciplinary 
team in charge in patients with LN highly suspicious for malignancy as defined by i) 
arterial hyperenhancement and washout, ii) arterial hyperenhancement and enhancing 
capsule, iii) arterial hyperenhancement and > 20 mm, iv) hypo/iso-enhancement and 
>20 mm/enhancing capsule/washout. Due to the observational design of the study, a 
RE: Ms JHEPAT-D-19-01279  
 
9
haemodynamic evaluation was performed only when clinically indicated as deemed by 
the multidisciplinary team in charge. In every patien , all laboratory and imaging studies 
were performed within 6 months of inclusion in the study. 
Baseline characteristics and blood tests 
The demographic (age and sex) and clinical data compiled were: type of 
congenital heart defect, FS surgical technique [atriopulmonary, lateral tunnel or 
extracardiac], New York Heart Association functional classification (NYHA), time 
since FS, height, weight, body mass index, alcohol abuse defined as >20 g/day in 
women and >30 g/day in men, and blood pressure. The following laboratory parameters 
were assessed: serum creatinine, total bilirubin, alanine aminotransferase, aspartate 
aminotransferase, gamma-glutamyl transferase (GGT), alkaline phosphatase, C-reactive 
protein, brain natriuretic peptide, serology (Ig HAV, HBV, HCV, and HIV), ferritin, 
transferrin, serum copper, ceruloplasmin, alpha-1-antitrypsin, alpha-fetoprotein, 
albumin, immunoglobulins, total serum proteins, haemogram, and international 
normalised ratio. 
Abdominal ultrasonography and liver elastography 
Fasting for at least 8 hours was required for both procedures. US was performed 
by a radiologist or a hepatologist with expertise in abdominal imaging (>10,000 
abdominal US). The following variables were assessed: a nodular liver surface 
appearance, parenchymal echogenicity (homogeneous or heterogeneous), right hepatic 
lobe size in the longitudinal axis, central suprahepatic vein diameter, long spleen axis, 
ascites (absence, minimal or moderate-severe), presenc  of gallstones, and number and 
characteristics of LN. These characteristics included their size (defined as the longest 
cross-sectional diameter), echogenicity (hypoechoic, isoechoic, or hyperechoic), shape 
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(round, ellipsoidal or irregular with unclear margins) and peripheral location (outer 
margins within 2 cm of the liver border).  
Liver elastography (Fibroscan®) was carried out by a trained operator (>1,000 
procedures) blinded to patient clinical history. In all cases, at least ten measurements 
were obtained. Only when there were more than ten valid measurements and an 
interquartile range < 30 were considered valid. The final result was drawn from an 
average value expressed in kilopascals (kPa). 
Abdominal MRI and CT scan 
MRI and CT protocols are provided in Supplementary material. The following 
characteristics of the nodules were systematically assessed: size (defined as the longest 
cross-sectional diameter), peripheral location using the definition described above, 
arterial phase enhancement, shape (round, ellipsoidal r irregular), washout in the portal 
venous phase defined as hypointensity or hypodensity i  part of, or in the whole lesion, 
on the portal venous and/or delayed phase compared to the surrounding liver 
parenchyma. We prospectively explored the behaviour f MRI/CT LI-RADS 
classification version 2014 [13]. Histological diagnosis of all biopsied nodules was 
recorded. 
Cardiovascular assessment 
Left ventricle ejection fraction was estimated by transthoracic echocardiography 
performed by cardiologists with expertise in congenital heart disease. The following 
parameters were recorded in the haemodynamic study: mean pulmonary artery pressure, 
inferior vena cava pressure, cardiac index calculated by Fick formula (L/min/m2), 
hepatic vein pressure, hepatic vein wedge pressure, and hepatic vein pressure gradient. 
When a prospective haemodynamic evaluation was not performed, haemodynamic data 
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were retrieved from the previous year if the patient had not undergone major cardiac 
surgery. 
Statistical analysis and sample size estimation 
Quantitative variables are expressed as mean and stard deviation (SD) or 
median and range when these were non-normally distributed. Normality was tested 
through distributional graphs and the Shapiro-Wilk test. Frequency counts and 
percentages were used for categorical data. 95% confidence intervals (CI) for 
proportions were calculated by the Wilson method. Continuous variables were tested 
using parametric (t-test) and nonparametric tests (Mann-Whitney U test) when 
appropriate. Chi-squared and Fisher’s exact tests were used for categorical data. 
Predictors of the presence of LN (any type of LN and LI-RADS ≥ 3) on MRI/CT were 
assessed by univariate and multivariate analysis. Variables found to be significant (P < 
0.1) in the univariate analysis were entered in a multivariable binomial logistic 
regression through backward stepwise modelling. Time since surgery was entered as a 
binary variable (≤ 10 vs > 10 years) in the logistic model to meet th assumption that 
independent variables must be linearly related to the logit of the outcome. This time 
threshold was based on previous position statements on FALD [12]. 
Based on previous reports, we assumed a prevalence of LN of 40% on MRI/CT 
[14]. Assuming an α value of 0.05, attrition rate of 5%, and an absolute error of 8%, our 
initial sample size estimation was 153. For multivariate analyses, the rule of a minimum 
of ten events per variable was used [15]. 
Sensitivity, specificity, likelihood ratios and predictive values of abdominal US 
for the diagnosis of LN (any type of LN and LI-RADS ≥ 3) were calculated, setting 
MRI/CT scan as the reference technique. Inter-test agreement between US and MRI/CT 
was calculated via the prevalence-adjusted and bias-adjusted kappa statistic [16]. 
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The following post-hoc univariate comparisons were performed to identify the 
reason for the low sensitivity of US found in the primary analysis: (1) LN seen on 
MRI/CT and not detected on US vs. LN seen on US and MRI/CT, (2) LN seen on US 
and not confirmed by MRI/CT vs LN seen on US and MRI/CT and (3) to address the 
possibility of a selection bias, we assessed any difference in results between patients 
who underwent all planned imaging procedures (n = 130) and the initial study 
population (n =152). Finally, an exploratory analysis was performed to assess whether 
the presence of two or more imaging signs of advanced chronic liver disease (blunt liver 
margin, heterogeneous liver parenchyma, portal vein> 13 mm, ascites or spleen long 
axis > 13 cm) were more common in patients with LN.
All tests were two-tailed.  Significance was set at P < 0.05. Data were analyzed 
at the promoting institution (Hospital Universitario Ramón y Cajal, Madrid) using 




  The number of patients enrolled was 152 (Figure 1, study flowchart). Mean 
age was 27.3 years (SD: 7.8); 83 were male (54.6%). The most common congenital 
heart defects treated with FS were tricuspid atresia (44.7%), double inlet left ventricle 
(22.4%) and pulmonary atresia (13.2%). The mean time from FS to inclusion was 18.3 
years (SD: 7.6). Extracardiac connection was the most frequent surgical procedure 
(64.5%). Although in 39 (25.7%) patients ejection fraction was below the normal range, 
the mean value in the whole cohort (56%) was within e normal limits (55 - 70%). 
Total bilirubin, transaminases, alpha-fetoprotein, C-reactive protein, and 
albumin were within the normal range; while mean GGT (100 IU/ml) was slightly 
increased. Seven patients (4.6%) showed elevated alpha-fetoprotein (normal range: 0 – 
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8 IU/mL), which was above 15 IU/mL in only two patients, who were subsequently 
diagnosed with hepatocellular carcinoma. Four patients were diagnosed with chronic 
HCV infection and one patient had previously achieved a sustained virologic response 
with antiviral treatment. Mean liver stiffness was 26.1 kPa (SD: 15.1). Hemodynamic 
data were available from 66 patients. Mean hepatic venous pressure gradient was 2 
mmHg (SD: 1.2, range: 0 – 6). Additional baseline characteristics are provided in Table 
1. 
Abdominal ultrasonography 
The prevalence of patients with LN on US was 29.6% (45/152; 95% CI: 22.9 – 
37.3%). The median number of nodules per patient was 2 nd mean nodule size was 11 
mm. Nodules were usually round (83.3%), hyperechoic (76.5%), and peripherally 
located in the liver (66.6%). Heterogeneous echogenicity (69.7%) and liver surface 
nodularity (54%) were frequent. Mean portal (10.2 mm) and central hepatic (8.9 mm) 
vein diameters were normal. Ascites was present in 29 patients (19.2%). Additional US 
findings are summarised in Table 2. 
MRI and CT  
Of the initial study population (n = 152), 130 patients underwent MRI (n = 93) 
or CT (n = 37). Nine patients refused MRI/CT; in 3 patients an MRI or CT scan was not 
deemed appropriate by the physician in charge due to poor heart functional status; and 
ten patients did not adhere to the protocol (in 3 patients > 6 months had elapsed between 
US and MRI/CT and 7 did not attend the scheduled visits for cross-sectional imaging). 
Demographic and clinical variables and LN prevalences and features were similar in 
patients that did or did not comply with the established protocol (Supplementary Table 
1).  
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A higher prevalence of LN was detected on MRI/CT than on abdominal US 
(62/130, 47.7%; 95% CI: 39.3 - 56.2%) amounting to a total of 173 nodules of median 
size 9 mm. Nodules were often hyperenhancing in the art rial phase (92.3%), round 
(90.3%), and peripherally located (74.8%). When theLI-RADS classification was 
applied, LI-RADS-3 nodules (59.4%) were the most frequent type. Eleven LN (7.1%) 
showed washout. Additional nodule characteristics on MRI/CT are provided in Table 3. 
In the univariate analysis, symptomatic protein-losing enteropathy (p = 0.026) 
and time since FS > 10 years (p = 0.037) were associated with the presence of LN 
(Table 4). In the logistic regression, only the latter remained as a significant predictor 
of any type of LN (FS > 10 years OR = 4.18, 95% CI:1.07 – 16.4; P = 0.040). 
Additionally, in the exploratory analysis, time since FS > 10 years was also the single 
predictor of LI-RADS ≥ 3 LN (OR = 4.23, 95% CI: 1.03 – 17.6; P = 0.046) 
(Supplementary Table 2). The number of patients with nodules paralleled the number 
of years elapsed from FS (upplementary Table 3). 
Summary of sensitivity, specificity and predictive values 
The sensitivity of US for the diagnosis of LN was 50% (95% CI: 37.9 - 62.1%) 
and specificity 85.3% (95% CI: 75 - 91.8%). Global accuracy was 68.5% (95% CI: 60 – 
75.8%).  
For tests restricted to the detection of LI-RADS ≥ 3 LN, sensitivity was 56% 
(95% CI: 42.3 - 68.8%) and specificity 83.8% (95% CI: 74.2 – 90.3%). Global accuracy 
was 73.1% (95% CI: 64.9 - 80%). Predictive values and likelihood ratios are provided 
in Supplementary Table 4 
  
Patients with liver nodules highly suspicious of malignancy 
RE: Ms JHEPAT-D-19-01279  
 
15
Table 5 describes the characteristics of the 8 patients (8/130, 6.1%) with LN 
highly suspicious of malignancy (i.e. LI-RADS 4-5) on cross-sectional imaging. US did 
not identify the LN in 2 of these 8 patients. Biopsy of LN was undertaken on 7 of these 
8 patients and showed hepatocellular carcinoma in 2 patients, and absence of 
malignancy in the other 5 (prevalence of hepatocellular carcinoma 1.3%). The 
hepatocellular carcinoma nodules were isoechoic on US and patients had elevated 
alpha-fetoprotein (272 and 339 IU/mL). One of these 2 patients had serologic features 
of spontaneous clearance of HCV infection (antiHCV+, HCV-RNA –) and had not 
received antiviral therapy; while the other lacked a ditional etiological factors of 
chronic liver disease. Finally, a patient with a 17 mm LN hypervascular and with 
washout, and with normal serum alfa-fetoprotein refus d to undergo biopsy. The LN of 
the latter patient has remained unchanged in 3- 6- and 12-month CT scans.  
 
Inter-test agreement and post-hoc analyses of liver nodules 
 Inter-test US vs. MRI/CT agreement was low (prevalence-adjusted and bias-
adjusted kappa statistic = 0.34). In ten patients, LN seen on US were not confirmed in 
the MRI/CT scan. These lesions were smaller (median s ze: 0.6 mm, P = 0.036) and 
more often hyperechoic (95.7%, P = 0.038) than LN detected with both imaging 
techniques (Supplementary Table 5). 
 In 31 out of 62 patients in whom LN were seen in the MRI/CT scan, US did not 
detect any lesion. LN exclusively detected on MRI/CT were more often hypervascular 
(96.6%, P = 0.03) than those identified with both imaging techniques (86.6%). No 
further significant differences were found (Supplementary Table 5). Interestingly, LN 
with biopsy-proven hepatocellular carcinoma  were detected by CT/MRI and US. 
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 The presence of ≥2 imaging signs of advanced chronic liver disease did not 









 This study prospectively examines the prevalence and imaging features of LN in 
a large series of Fontan patients. Our findings indicate that i) LN are common and their 
frequency increases in parallel to the time elapsed since Fontan  surgery, ii) US shows a 
rather low sensitivity to identify LN, iii) most of these nodules show hypervascular 
behaviour on CT/MRI but result on non-neoplastic regenerative hepatocytes, and iv) 
hepatocellular carcinoma is a possibility, albeit unlikely. 
Liver nodules were detected in approximately half of the study participants. 
Reported prevalences of LN in patients with FALD have been lower, ranging from 17 to 
40% [7,8,14,17,18]. The higher prevalence detected h re could be explained by the 
exclusive use of US or the retrospective and non-systematic assessment of LN in 
previous studies. In addition,  our cohort showed a higher mean time since FS, which is 
a known risk factor for advanced chronic liver disea  and hepatic complications 
[5,12,19,20]. 
Upon US, we observed that LN were commonly hyperechoic, < 2 cm, multiple, 
and located in the periphery of the liver, in line with the findings of US studies 
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conducted on smaller samples [17,21]. Some nodules, especially when small (< 1 cm) 
and hyperechoic, were not reproduced in the MRI/CT scan. According to some authors, 
some of these LN exclusively visible on US examination could represent small areas 
with microvascular disturbances or early-stage fibrosis [17]. As expected, additional 
signs suggestive of liver disease such as liver contour nodularity, heterogeneous 
parenchyma and ascites were commonly encountered. Interestingly, our results show 
that classical imaging signs of advanced chronic liver disease do not predict the 
presence of LN. 
One of our main findings was that the sensitivity of US for the diagnosis of LN 
was low. This could be because US is more operator-dependent than MRI/CT scanning 
and the vascular nature of LN in FALD. Actually, some lesions were only seen in the 
arterial phase after contrast injection and arterial hyperenhancement was more common 
in LN that were not detected by US. In a recent study examining 49 Fontan patients, it 
was found that LN were missed on US in approximately 30% of cases [8]. Taken 
together, these observations suggest that contrast-enhanced modalities may be more 
suitable to identify the full spectrum of LN in patients with FALD. US did not detect 
any LN in two patients with LI-RADS 5 lesions, but very importantly did not miss any 
case of hepatocellular carcinoma in our cohort and, consequently, we cannot conclude 
from our data that this imaging modality should be ruled out as a screening tool. To 
date, only one study has assessed the benefits of surveillance imaging in FALD [22]. 
Because of the retrospective design and heterogeneity of intervals and imaging 
techniques in this study, the authors could only recommend surveillance. However, the 
optimal management strategy for these patients remains to be established. 
A high risk of hepatocellular carcinoma is a major c ncern and this is what 
prompted our study. However, despite the high prevalence of LN in our FS cohort, the 
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proportion of malignant LN was low. Post-mortem series and biopsy studies have 
shown that most LN correspond to focal nodular hyperplasia (FNH) or benign 
regenerative nodules [6,7,18,21,23]. FNH is a polycl nal lesion occurring in the setting 
of normal parenchyma and has been linked to a hyperplastic response to increased blood 
flow induced by a focal vascular abnormality [24]. As shown here, hepatic adenoma 
may also appear after FS and there have been some case reports in FALD [23]. 
Adenoma underdiagnosis is a possibility, as these may resemble FNH-like lesions in 
terms of size, imaging and histological features [25]. In some of our patients with 
biopsy-proven non-malignant lesions washout features w re found. Interestingly, a low 
specificity of washout to diagnose hepatocellular ccinoma has been also recently 
described in a French cohort of patients with BCS [26]. In another recent study, it was 
shown that benign hyperenhancing nodules detected af r FS may display washout and 
be mistaken for hepatocellular carcinoma according to imaging criteria [18]. As shown 
in our two patients with hepatocellular carcinoma, alpha-fetoprotein is usually elevated 
in cases of malignancy, as occurs in BCS [10,11,27,28]. Based on our results, we would 
argue that the hepatocellular carcinoma diagnostic criteria used in cirrhosis are not 
applicable in FALD, and biopsy confirmation is always required [9,18,23].  
The origin of LN has been linked to perfusion disturbances in the liver 
parenchyma secondary to Fontan circulation, similar to the nodules encountered in BCS 
and other vascular liver diseases [6,7,18,24]. It should be noted that extrapolating data 
from BCS and other forms of liver cirrhosis may be inaccurate, since the portal 
hypertension model in FALD is characteristically hypodynamic and arterial splanchnic 
perfusion may also be impaired, as shown in Doppler studies [29].  In fact, this is what 
makes FALD a unique entity. Some authors propose that impaired hepatic venous 
outflow caused by elevated right central pressures leads to atrophy and hypoxia-induced 
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damage, followed by a compensatory mechanism characterised by the arterialisation of 
liver parenchyma and regenerative changes [7,14]. Elevated right pressures and liver 
stiffness have also been described as potential markers of LN in univariate analyses of 
previous studies, but these results were not reproduced here [7,8]. Inflammation and 
cholestatic-induced injury are thought to play a minor role in LN and FALD progression 
[5,7,23]. In contrast, we identified time since FS > 10 years as a predictive factor for 
LN. This is an important finding providing further support for the expert-based 
consensus that liver assessment is mandatory 10 years after FS [30].  
Our study has some limitations. First, it could be argued that some lesions that 
were not biopsied could harbour hepatocellular carcinoma. However, available data 
suggest that hepatocellular carcinoma in FALD usually presents with suspicious 
radiological features (i.e. hyperenhancing nodules with washout) or elevated alpha-
fetoprotein. Moreover, liver biopsy in patients with elevated systemic pressures who are 
frequently under antithrombotic treatment carries a ignificant risk of adverse events. 
Considering that all but one patient with LN showing worrisome features underwent 
biopsy, we believe that the risk of underdiagnosed h patocellular carcinoma is likely to 
be low. Secondly, some patients did not undergo the same cross-sectional imaging. CT 
scanning was reserved for patients in whom MRI was contraindicated to minimize 
radiation exposure in this young population. Further, according to a recent report, 
agreement between MRI and CT is high in the FALD setting (kappa statistic = 0.85) [8]. 
Third, LI-RADS classification has been developed to standardise the reporting of LN in 
patients with cirrhosis, but it has not been validate  in patients with FALD. Therefore, 
the LI-RADS sub-analysis in our series should be rega ded as merely exploratory, since 
the absence of validation of LI-RADS criteria in FALD precludes its application in this 
population. Finally, our study design precluded anyssessment of the natural history of 
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LN in the long-term. We anticipate that further longitudinal study of this cohort will 
shed some light on this issue.  
In conclusion, LN frequently appear in FALD and may not be detected in an US 
exam. These nodules are usually hyperechoic, hypervascular, mainly located in the liver 
periphery and are more often encountered later thanen years after FS. The risk of 
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Table 1. Baseline characteristics 
 
Number of patients 
Age, years  
Male sex 







Cardiologic and haemodynamic assessment 
Main congenital heart defect 
Tricuspid atresia 




Mitral valve atresia 
Other 




Time since Fontan connection, years 
Pacemaker 
Flutter/atrial fibrillation 





Systolic blood pressure, mmHg 
Diastolic blood pressure, mmHg 
Oxygen saturation, % 
Ejection fraction on echocardiography, % 
 
Haemodynamic study (n=66) 
Pulmonary artery medium pressure, mmHg 
Inferior vena cava, mmHg 
Cardiac index, L/min/m2 
Free Hepatic vein pressure, mmHg 
Wedged Hepatic vein  pressure, mmHg 




























































Alkaline phosphatase, IU/L 
Gamma-glutamyl transferase, IU/L 
Albumin, g/dL 
Total proteins, g/dL 
BNP, pg/mL 
Ig G, mg/dL 
Ig A, mg/dL 



































Quantitative variables are provided as means (standard deviation) or median 
(interquartile range). Qualitative variables are expr ssed as absolute values and 
percentages. 
AVSD: atrioventricular septal defect, NYHA: New York Heart Association, ALT: 
alanine transaminase, AST: aspartate aminotransferase, BNP: brain natriuretic peptide, 
HBsAg: Hepatitis B surface antigen, HCV: Hepatitis C virus, MELD-XI: model for 
end-stage liver disease excluding INR. 
  




Table 2. Ultrasonographic findings  
 
Number of patients 
Liver surface nodularity 
Heterogeneous echogenicity 
Righ hepatic lobe, cm 
Portal vein diameter, mm 
Central hepatic vein diameter, mm 
Spleen diameter, cm 

















Patients with one or more hepatic nodules 
No. of patients 
Median no. of nodules per patient 
Total no. of nodules * 
Median size, mm 
No. of patients with one or more nodules 
≥ 1 cm 
Median size of the largest nodule, mm 
















































Quantitative variables are provided as means (standard deviation) or median 
(interquartile range). Qualitative variables are expr ssed as absolute values and 
percentages. 
* Five patients with countless micronodules were excluded from the analysis of nodule 
characteristics. 
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Table 3. Hepatic nodules in patients undergoing MRI or CT  
Number of patients 
MRI 
CT  
Patients with one or more nodules 
Total number of nodules  
No. of nodules per patient  
Size, mm 
Size of the largest nodule, mm 
No. of patients with one or more nodules ≥ 1 cm 












No. of nodules assessed for characteristics (n: 155) * 
































































6 (5.7 %) 
7 (6.6 %) 
 
6 (5.7 %) 
85 (80.2%) 
8 (7.5%) 
7 (6.6 %) 
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Quantitative variables are provided as means (standard deviation or median 
[interquartile range]). Qualitative variables are expressed as absolute values and 
percentages. 
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Table 4. Predictors of liver nodules on MRI or CT  
 






Multivariate logistic regression 
Odds ratio (confidence interval 95%) P-value 
Number of patients (n = 130) 
Age, years 
Male Sex 
Time Fontan connection > 10 years 
Enteropathy 
Body mass index 





Alkaline phosphatase, IU/L 
Gamma-glutamyl transferase, IU/L 
Brain natriuretic peptide, pg/mL 
Alpha-fetoprotein, IU/mL 
Ventricle ejection fraction, % 
Haemodynamic (n = 66) 
Pulmonary artery medium 
pressure, mmHg 
Inferior vena cava, mmHg 
Cardiac index, L/min/m2 
Liver stiffness, kPa 









































































4.18 (1.07 – 16.4); P = 0.040 
3.84 (0.98 – 14.9); P = 0.053  
 
Quantitative variables are provided as means and qualitative variables as absolute values and percentag s. Figures in bold indicate significance. 
kPa: kilopascals. 



























Extracardiac 17.7 55.2 4 No. 1: 17 
mm round 
hyperechoic 
Nos. 2, 3: 6 
mm round 
hyperechoic  








Core biopsy nodule No.1: 
negative for malignancy 
3-month imaging 
follow up  
Female 
38.3 








Hepatocellular carcinoma Radiofrequency 
Male 
33 
Atriopulmonar 27.4 48 1.3 No. 1: 10 
mm round 
hyperechoic  
No. 2: 6 
mm round 
hyperechoic 
No. 3: 5 
mm round 
hyperechoic 








Core biopsy nodule No.1: 






Atriopulmonar 15.6 11.6 1 No No. 1: 14 mm, 
hypervascular, 



















Core biopsy nodule No. 1: 
negative for malignancy 
Male 
26 
Atriopulmonar 19.2 70 339 No. 1: 40 
mm round, 
Isoechoic 
No. 2: 18 
mm round 
hypoechoic 
































Atriopulmonar 25 73.5 2 No No. 1: 16 mm, 
hypervascular, 

















Extracardiac 16.5 35.3 1.2 20 mm 
round 
hyperechoic 




Not performed 3- and 12-month 
















CT: computerised tomography; MRI: magnetic resonance imaging; NYHA: New York 
Heart Association; US: ultrasonography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
